American Journal of Engineering & Natural Sciences (AJENS) ISSN 2074-112X

Original Research Contributions in Genetic Biongineering And Natural Genome Editing

fallback-image

Antibodyes

Tissue and Cell Extraction and Purification

EP10011 100 Tests
EUR 444.6

All Competitors Laboratories manufactures the antibodyes reagents distributed by Genprice. The Antibodyes reagent is RUO (Research Use Only) to test human serum or cell culture lab samples. To purchase these products, for the MSDS, Data Sheet, protocol, storage conditions/temperature or for the concentration, please contact All Competitors. Other Antibodyes products are available in stock. Specificity: Antibodyes Category:

True Blue

1mg Ask for price
Description: True Blue

True Blue

50mg Ask for price
Description: True Blue

True Blue

5mg Ask for price
Description: True Blue

JBS True Blue

300µl
EUR 11.84

JBS True Blue

300 µl
EUR 16
Description: JBS True Blue

True Blue Chloride

100mg
EUR 11200
Description: 71431-30-6

True Blue Chloride

100 mg Ask for price

True Blue Diaceturate Salt

100mg
EUR 15000
Description: 108321-12-6

True north Cryobox1.5/2mLNatural

PK10
EUR 129.6

True Blue Diaceturate Salt

100 mg Ask for price

True Blue (TB) Diaceturate Salt

1mg Ask for price
Description: 108321-12-6

True Blue (TB) Diaceturate Salt

5mg Ask for price
Description: 108321-12-6

Serum / Plasma information

MERS antibody-2E6 (IgG) Humanized Antibody

MBS8574776-5x005mg 5x0.05mg
EUR 2015

MSH6 antibody | 3E1

MBS226404-01mL 0.1mL
EUR 485

MSH6 antibody | 3E1

MBS226404-5x01mL 5x0.1mL
EUR 2015

CTLA-4 Antibody [1E6]

MBS154535-01mg 0.1mg
EUR 500

CTLA-4 Antibody [1E6]

MBS154535-5x01mg 5x0.1mg
EUR 2230

PDL2 Antibody [4E10]

MBS154565-01mg 0.1mg
EUR 500

PDL2 Antibody [4E10]

MBS154565-5x01mg 5x0.1mg
EUR 2230

PDL1 Antibody [8E12]

MBS154571-01mg 0.1mg
EUR 500

PDL1 Antibody [8E12]

MBS154571-5x01mg 5x0.1mg
EUR 2230

TIGIT Antibody [7E5]

MBS154588-01mg 0.1mg
EUR 500

TIGIT Antibody [7E5]

MBS154588-5x01mg 5x0.1mg
EUR 2230

VISTA Antibody [9E4]

MBS154606-01mg 0.1mg
EUR 500

VISTA Antibody [9E4]

MBS154606-5x01mg 5x0.1mg
EUR 2230

ARF1 antibody | E01/8D1

MBS226266-01mL 0.1mL
EUR 485

ARF1 antibody | E01/8D1

MBS226266-5x01mL 5x0.1mL
EUR 2015

ARNT antibody | E01/1H8

MBS226268-01mL 0.1mL
EUR 485

ARNT antibody | E01/1H8

MBS226268-5x01mL 5x0.1mL
EUR 2015

INI-1 antibody | E01/5G8

MBS226383-01mL 0.1mL
EUR 485

INI-1 antibody | E01/5G8

MBS226383-5x01mL 5x0.1mL
EUR 2015

PDK4 Antibody (E265)

MBS9204754-008mL 0.08mL
EUR 210

PDK4 Antibody (E265)

MBS9204754-04mL 0.4mL
EUR 430

PDK4 Antibody (E265)

MBS9204754-5x04mL 5x0.4mL
EUR 1910

CTLA4 Antibody [1E6]

RF16011-002mg 0.02 mg
EUR 229.7
Description: The cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), also known as CD152, is a member of the immunoglobulin superfamily that is expressed by activated T cells and transmits an inhibitory signal to T cells (1,2). Both it and the homologous T-cell co-stimulatory protein CD28 bind to CD80 (B7-H1) and CD86 (B7-H2) on antigen-presenting cells (APCs) (3). Mutations in the CTLA-4 gene have been implicated in multiple autoimmune diseases (4). CTLA-4 also functions as an immune checkpoint protein, and anti- CTLA-4 antibodies have been successfully used in the treatment of cancer (5).

CTLA4 Antibody [1E6]

RF16011-01mg 0.1 mg
EUR 594.26
Description: The cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), also known as CD152, is a member of the immunoglobulin superfamily that is expressed by activated T cells and transmits an inhibitory signal to T cells (1,2). Both it and the homologous T-cell co-stimulatory protein CD28 bind to CD80 (B7-H1) and CD86 (B7-H2) on antigen-presenting cells (APCs) (3). Mutations in the CTLA-4 gene have been implicated in multiple autoimmune diseases (4). CTLA-4 also functions as an immune checkpoint protein, and anti- CTLA-4 antibodies have been successfully used in the treatment of cancer (5).

PDL2 Antibody [4E10]

RF16021-002mg 0.02 mg
EUR 229.7
Description: PD-L2 Antibody: Cell-mediated immune responses are initiated by T lymphocytes that are themselves stimulated by co gnate peptides bound to MHC molecules on antigen-presenting cells (APC). T-cell activation is generally self-limited as activated T cells express receptors such as PD-1 (also known as PDCD-1) that mediate inhibitory signals from the APC. PD-1 can bind two different but related ligands, PD-L1 and PD-L2, both of which are thought act as a negative regulator of T cell activation. However, it has been suggested that PD-L2 can act to stimulate an immunogenic response through and alternative receptor from PD-1.

PDL2 Antibody [4E10]

RF16021-01mg 0.1 mg
EUR 594.26
Description: PD-L2 Antibody: Cell-mediated immune responses are initiated by T lymphocytes that are themselves stimulated by co gnate peptides bound to MHC molecules on antigen-presenting cells (APC). T-cell activation is generally self-limited as activated T cells express receptors such as PD-1 (also known as PDCD-1) that mediate inhibitory signals from the APC. PD-1 can bind two different but related ligands, PD-L1 and PD-L2, both of which are thought act as a negative regulator of T cell activation. However, it has been suggested that PD-L2 can act to stimulate an immunogenic response through and alternative receptor from PD-1.

PDL1 Antibody [8E12]

RF16032-002mg 0.02 mg
EUR 229.7
Description: PD-L1 Antibody: Cell-mediated immune responses are initiated by T lymphocytes that are themselves stimulated by cognate peptides bound to MHC molecules on antigen-presenting cells (APC) (1). T-cell activation is generally self-limited as activated T cells express receptors such as PD-1 (also known as PDCD-1) that mediate inhibitory signals from the APC (2). PD-1 can bind two different but related ligands, PD-L1 and PD-L2. PD-L1 is a B7-related protein that inhibits cell-mediated immune responses by reducing the secretion of IL-2 and IL-10 from memory T cells (3). This suggests that PD-L1 may be useful in reducing allogenic CD4+ memory T-cell responses to endothelial cells, thereby reducing the likelihood of host immune responses to allografts. PD-L1 also functions as an immune checkpoint protein, and multiple anti-PD-L1 antibodies are currently in phase II and III clinical trials, with one antibody already approved for the treatment of cancer (4).

PDL1 Antibody [8E12]

RF16032-01mg 0.1 mg
EUR 594.26
Description: PD-L1 Antibody: Cell-mediated immune responses are initiated by T lymphocytes that are themselves stimulated by cognate peptides bound to MHC molecules on antigen-presenting cells (APC) (1). T-cell activation is generally self-limited as activated T cells express receptors such as PD-1 (also known as PDCD-1) that mediate inhibitory signals from the APC (2). PD-1 can bind two different but related ligands, PD-L1 and PD-L2. PD-L1 is a B7-related protein that inhibits cell-mediated immune responses by reducing the secretion of IL-2 and IL-10 from memory T cells (3). This suggests that PD-L1 may be useful in reducing allogenic CD4+ memory T-cell responses to endothelial cells, thereby reducing the likelihood of host immune responses to allografts. PD-L1 also functions as an immune checkpoint protein, and multiple anti-PD-L1 antibodies are currently in phase II and III clinical trials, with one antibody already approved for the treatment of cancer (4).

Recent Posts

April 2026
M T W T F S S
 12345
6789101112
13141516171819
20212223242526
27282930  

Tags

Categories